Search
Results
showing 1-10 of 2258
Global Health Watch: First real-world PEPFAR disruption data, long-term LEN results, US foreign assistance, HIV supply chain vulnerabilities
July 2026
New evidence ahead of next week’s International AIDS Conference continues to illustrate the challenges and opportunities facing the global HIV response. This week’s issue covers the first real-world evidence of PEPFAR disruptions, new data reinforcing the long-term potential of lenacapavir for HIV PrEP (LEN), the emerging US foreign assistance architecture and a timely analysis of the vulnerabilities facing HIV medicine supply chains.
AVAC Infographics for AIDS 2026
July 2026
For those presenting at AIDS 2026, AVAC’s latest infographics on the research and development pipeline, prevention options, and the impact of US funding cuts can be accessed here. We hope these are useful for presentations and discussions at the conference and beyond.
AVAC and Access Bridge Applaud Monthly PrEP Pill Access Announcement; Call for Speed, Scale and Equity in Future Monthly Oral Alimatravir Introduction
July 2026
AVAC and Access Bridge applaud Merck’s announcement today that it has granted seven direct licenses to generic manufacturers to produce their investigational monthly pill for HIV prevention, known as MK-8527, or alimatravir, while Phase 3 clinical trials are still enrolling. “Today’s news reflects truly positive momentum in future access to alimatravir for PrEP, if proven safe and effective,” said Mitchell Warren, AVAC’s executive director.
Years Ahead in HIV Prevention Research: Time to Market
July 2026
This timeline shows the potential time points when the next-generation of HIV prevention options might find their way into new programs.
CASPR Impact Report: Celebrating Growth, Inspiring the Future
July 2026
AVAC is proud to release the CASPR Impact Report: Celebrating Growth, Inspiring the Future, celebrating what is possible when long-term investment in African leadership, partnerships and coalition-based advocacy is matched with shared purpose. CASPR, the Coalition to Accelerate and Support Prevention Research, proved that community-led coalitions are central to turning innovation into action, and ensuring that advances in HIV prevention are shaped by the people they are meant to serve.
Lenacapavir Implementation Studies
July 2026
Ongoing and planned implementation studies for the lenacapavir as of July 2026.
Injectable PrEP Regulatory Approvals
July 2026
This graphic tracks regulatory approvals for injectable Cabotegravir and Lenacapavir for PrEP as of July 2026.
Global Health Watch: 500,000 oppose White House grant rule, CDC & PEPFAR’s future, global health transition strategy, Gawande & AIDS 2026, issue 77
July 2026
More than half a million comments were submitted in response to the White House’s proposal to politicize federal research grants – with a significant majority opposing it. At the same time, questions mounted over the future of the CDC, PEPFAR, and the Administration’s vision for transitioning US global health programs. This week also features reflections from former USAID global health leader Atul Gawande on the human cost of dismantling USAID and the likely discussions ahead at AIDS 2026 on the consequences of US policy changes for HIV programs and global health.
Potential Lenacapavir Supply, 2026-28
July 2026
Lenacapavir has the potential to reach millions — and the momentum is building. Using the current oral PrEP market as a baseline, this graphic estimates what demand for LEN could look like through 2028 and shows how current donor commitments stack up against that opportunity.
HIV Prevention Pipeline: Products to Watch
July 2026
From the People’s Research Agenda, this graphic tracks the pipeline of potential new HIV prevention options across broadly neutralizing antibodies, preventive vaccines, pre-exposure prophylaxis, and multipurpose technologies.
showing 1-10 of 2258